CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
出版年份 2015 全文链接
标题
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
作者
关键词
-
出版物
Frontiers in Oncology
Volume 5, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2015-06-01
DOI
10.3389/fonc.2015.00123
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer
- (2014) Hanna Sallinen et al. BMC CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
- (2014) M. F. Sanmamed et al. CLINICAL CANCER RESEARCH
- Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
- (2014) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
- (2014) Jung-Min Lee et al. JNCI-Journal of the National Cancer Institute
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy
- (2014) Shahrzad Jalali et al. NEURO-ONCOLOGY
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
- (2013) J.-m. Lee et al. ANNALS OF ONCOLOGY
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
- (2013) William L. Dahut et al. BJU INTERNATIONAL
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
- (2013) Sook Ryun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
- (2013) A. B. Nixon et al. CLINICAL CANCER RESEARCH
- Targeting IL-8 signalling to inhibit breast cancer stem cell activity
- (2013) Jagdeep K Singh et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review
- (2013) Antonio Macciò et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort
- (2013) Nilofer Azad et al. MOLECULAR & CELLULAR PROTEOMICS
- Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer
- (2012) Niyati J. Nadkarni et al. CANCER LETTERS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
- (2012) Dana M. Chase et al. GYNECOLOGIC ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab †
- (2011) D. Malka et al. ANNALS OF ONCOLOGY
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib
- (2011) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
- (2011) Shivaani Kummar et al. EUROPEAN JOURNAL OF CANCER
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal treatment for relapsing ovarian cancer
- (2010) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
- (2010) P. G. Nikolinakos et al. CANCER RESEARCH
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
- (2010) D. C. Hegan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of dynamic contrast enhanced MR imaging in cancer diagnosis and treatment
- (2009) Baris Turkbey et al. Diagnostic and Interventional Radiology
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
- (2009) Emer O. Hanrahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone H2AX is integral to hypoxia-driven neovascularization
- (2009) Matina Economopoulou et al. NATURE MEDICINE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study
- (2008) Raina N. Fichorova et al. ANALYTICAL CHEMISTRY
- PARP-1 Inhibition Prevents Oxidative and Nitrosative Stress–Induced Endothelial Cell Death via Transactivation of the VEGF Receptor 2
- (2008) Marlene T. Mathews et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
- (2008) R. J. Kinders et al. CLINICAL CANCER RESEARCH
- Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay
- (2008) Nathalie Jacques et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth
- (2008) William M. Merritt et al. JNCI-Journal of the National Cancer Institute
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started